Cayman Chemical Company Incorporated

Aerie Pharmaceuticals, Inc.

Abbott Laboratories Corporation

Abbvie Inc.

Gilles Chambournier

Victor Fedij

Hussein Mahmoud Mahmoud

Gregory William Endres

Kirk William Hering

Mitchell Anthony deLong

Chih-hung Lee

Arthur Gomtsyan

John R Koenig

Erol K Bayburt

Robert G Schmidt

Kirill A Lukin

Russell Drew Cink

Margaret Chi-Ping Hsu

Jill Marie Sturdivant

Marvin Robert Leanna

Thomas James Krell, Ii

Michael G Pamment

Stephen Douglas Barrett

Andriy Kornilov

Robert M Leanna

Ivan Vesely

Chih-Hung Lee

Margaret Hsu

Thomas James Ii Krell

Russel D Cink

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

Process for the preparation of kinase inhibitors and intermediates thereof

The present invention provides processes for preparing a prostacyclin analog of Formula I or a pharmaceutically acceptable salt thereof, wherein Ris a linear or branched Calkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.

Methods of synthesizing a prostacyclin analog

The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.

Amine salts of a prostacyclin analog

The present invention provides processes for preparing a prostacyclin analog of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ris a linear or branched Calkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.

The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts. 

Described are methods for the preparation of 6-aminoisoquinoline, a useful intermediate compound in the synthesis of kinase inhibitors.

Methods for the preparation of 6-aminoisoquinoline

A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.

Process for the preparation of F-series prostaglandins

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X-X, R-R, Z-Zand Arare defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention discloses novel compounds of general formula (I) 

Growing community of inventors

Ann Arbor, MI, United States of America

Gilles Chambournier